These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28302060)

  • 21. [Chronic heart failure].
    Hradec J
    Cas Lek Cesk; 2015; 154(6):260-8. PubMed ID: 26750621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
    Shah RV; Desai AS; Givertz MM
    J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The contribution of comorbidities to mortality in hospitalized patients with heart failure.
    Riedel O; Ohlmeier C; Enders D; Elsässer A; Vizcaya D; Michel A; Eberhard S; Schlothauer N; Berg J; Garbe E
    Clin Res Cardiol; 2018 Jun; 107(6):487-497. PubMed ID: 29404680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2,258 hospitalized patients.
    Varadarajan P; Pai RG
    J Card Fail; 2003 Apr; 9(2):107-12. PubMed ID: 12751131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
    Fonarow GC; Stough WG; Abraham WT; Albert NM; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Am Coll Cardiol; 2007 Aug; 50(8):768-77. PubMed ID: 17707182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.
    Kristensen SL; Jhund PS; Køber L; Preiss D; Kjekshus J; McKelvie RS; Zile MR; Anand IS; Wikstrand J; Wedel H; Komajda M; Carson PE; Cleland JG; McMurray JJ
    Eur J Heart Fail; 2015 Feb; 17(2):169-76. PubMed ID: 25756844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    MacDonald MR; Petrie MC; Varyani F; Ostergren J; Michelson EL; Young JB; Solomon SD; Granger CB; Swedberg K; Yusuf S; Pfeffer MA; McMurray JJ;
    Eur Heart J; 2008 Jun; 29(11):1377-85. PubMed ID: 18413309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource Utilization in Patients With Heart Failure and Preserved Versus Reduced Ejection Fraction.
    Nichols GA; Reynolds K; Kimes TM; Rosales AG; Chan WW
    Am J Cardiol; 2015 Oct; 116(7):1088-92. PubMed ID: 26235928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Care and outcomes of Hispanic patients admitted with heart failure with preserved or reduced ejection fraction: findings from get with the guidelines-heart failure.
    Vivo RP; Krim SR; Krim NR; Zhao X; Hernandez AF; Peterson ED; Piña IL; Bhatt DL; Schwamm LH; Fonarow GC
    Circ Heart Fail; 2012 Mar; 5(2):167-75. PubMed ID: 22414939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart failure with normal ejection fraction is uncommon in acute myocardial infarction settings but associated with poor outcomes: a study of 91,360 patients admitted with index myocardial infarction between 1998 and 2010.
    Desta L; Jernberg T; Spaak J; Hofman-Bang C; Persson H
    Eur J Heart Fail; 2016 Jan; 18(1):46-53. PubMed ID: 26503670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit.
    Buckley LF; Carter DM; Matta L; Cheng JW; Stevens C; Belenkiy RM; Burpee LJ; Young MA; Weiffenbach CS; Smallwood JA; Stevenson LW; Desai AS
    JACC Heart Fail; 2016 Jan; 4(1):1-8. PubMed ID: 26656139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States.
    Greene SJ; Triana TS; Ionescu-Ittu R; Burne RM; Guérin A; Borentain M; Kessler PD; Tugcu A; DeSouza MM; Felker GM; Chen L
    JACC Heart Fail; 2020 Nov; 8(11):943-953. PubMed ID: 32800512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).
    Ambrosy AP; Bhatt AS; Gallup D; Anstrom KJ; Butler J; DeVore AD; Felker GM; Fudim M; Greene SJ; Hernandez AF; Kelly JP; Samsky MD; Mentz RJ
    Am J Cardiol; 2017 Jul; 120(1):98-105. PubMed ID: 28479167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction.
    Coiro S; Girerd N; McMurray JJV; Pitt B; Swedberg K; van Veldhuisen DJ; Lamiral Z; Rossignol P; Zannad F
    Clin Res Cardiol; 2021 Aug; 110(8):1308-1320. PubMed ID: 33956209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).
    Wong CM; Hawkins NM; Jhund PS; MacDonald MR; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; McMurray JJ
    J Am Coll Cardiol; 2013 Nov; 62(20):1845-54. PubMed ID: 23850914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes.
    Steinberg BA; Zhao X; Heidenreich PA; Peterson ED; Bhatt DL; Cannon CP; Hernandez AF; Fonarow GC;
    Circulation; 2012 Jul; 126(1):65-75. PubMed ID: 22615345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The burden of preserved ejection fraction heart failure in a real-world Swedish patient population.
    Stålhammar J; Stern L; Linder R; Sherman S; Parikh R; Ariely R; Deschaseaux C; Wikström G
    J Med Econ; 2014 Jan; 17(1):43-51. PubMed ID: 24066839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
    Florea VG; Rector TS; Anand IS; Cohn JN
    Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27413037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional mitral regurgitation at discharge and outcomes in patients hospitalized for acute decompensated heart failure with a preserved or reduced ejection fraction.
    Kajimoto K; Sato N; Takano T;
    Eur J Heart Fail; 2016 Aug; 18(8):1051-9. PubMed ID: 27212582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.